Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.
The 'Berlin Patient', who maintains suppressed levels of HIV viremia in the absence of antiretroviral therapy, continues to be a standard bearer in HIV eradication research. However, the unique circumstances surrounding his functional cure are not applicable to most HIV(+) patients. To achieve a functional or sterilizing cure in a greater number of infected individuals worldwide, combinatorial treatments, targeting multiple stages of the viral life cycle, will be essential. Several anti-HIV gene therapy approaches have been explored recently, including disruption of the C-C chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) coreceptor loci in CD4(+) T cells and CD34(+) hematopoietic stem cells. However, less is known about the efficacy of these strategies in patients and more relevant HIV model systems such as non-human primates (NHPs). Combinatorial approaches, including genetic disruption of integrated provirus, functional enhancement of endogenous restriction factors and/or the use of pharmacological adjuvants, could amplify the anti-HIV effects of CCR5/CXCR4 gene disruption. Importantly, delivering gene disruption molecules to genetic sites of interest will likely require optimization on a cell type-by-cell type basis. In this review, we highlight the most promising gene therapy approaches to combat HIV infection, methods to deliver these therapies to hematopoietic cells and emphasize the need to target viral replication pre- and post-entry to mount a suitably robust defense against spreading infection.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
C W
CW
Peterson
P
P
Younan
K R
KR
Jerome
H-P
HP
Kiem
D018952:Antigens, CD34 / Q000235:genetics / Q000276:immunology; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D015316:Genetic Therapy; D015658:HIV Infections / Q000235:genetics* / Q000628:therapy* / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000472:pathogenicity; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D058990:Molecular Targeted Therapy; D019713:Receptors, CCR5 / Q000235:genetics; D019718:Receptors, CXCR4 / Q000235:genetics; D014779:Virus Replication / Q000235:genetics*
D018952:Antigens, CD34; C527276:CXCR4 protein, human; D019713:Receptors, CCR5; D019718:Receptors, CXCR4